ETF Holdings Breakdown of LGND

Stock NameLigand Pharmaceuticals Incorporated
TickerLGND(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS53220K5048
LEI5493008K7TB0IKP37H79

News associated with LGND

State of Alaska Department of Revenue Sells 269 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
State of Alaska Department of Revenue decreased its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.5% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 10,470 shares of the biotechnology company’s stock after selling 269 shares during the quarter. State of Alaska Department of Revenue’s holdings in Ligand Pharmaceuticals were worth […] - 2025-06-26 07:44:48
Opal Wealth Advisors LLC Purchases Shares of 305 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Opal Wealth Advisors LLC purchased a new stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund purchased 305 shares of the biotechnology company’s stock, valued at approximately $32,000. A number of other hedge funds have […] - 2025-06-17 07:58:58
Handelsbanken Fonder AB Has $700,000 Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Handelsbanken Fonder AB raised its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 13.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,658 shares of the biotechnology company’s stock after buying an additional 800 shares during […] - 2025-06-16 08:01:01
Rhumbline Advisers Trims Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Rhumbline Advisers cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 57,456 shares of the biotechnology company’s stock after selling 1,989 shares during the period. Rhumbline Advisers’ holdings in Ligand Pharmaceuticals […] - 2025-06-13 07:36:56
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $146.14 Average Price Target from Analysts
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) has earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have updated their coverage on the stock […] - 2025-06-13 05:32:49
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 10,563 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 26.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 50,401 shares of the biotechnology company’s stock after […] - 2025-06-03 08:13:09
Squarepoint Ops LLC Acquires Shares of 16,799 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Squarepoint Ops LLC acquired a new stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) during the fourth quarter, HoldingsChannel reports. The fund acquired 16,799 shares of the biotechnology company’s stock, valued at approximately $1,800,000. Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Smartleaf Asset Management […] - 2025-05-30 09:09:00
Bank of America Corp DE Has $11.51 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Bank of America Corp DE lifted its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 107,439 shares of the biotechnology company’s stock after buying an additional 2,533 shares during the quarter. Bank of America Corp DE’s holdings in Ligand Pharmaceuticals […] - 2025-05-23 07:36:48
Jane Street Group LLC Sells 1,083 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Jane Street Group LLC reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 7.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,369 shares of the biotechnology company’s stock after selling 1,083 shares during the quarter. Jane Street Group LLC’s […] - 2025-05-20 07:30:46
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $146.14 Consensus Target Price from Analysts
Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) have earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have updated their coverage on the stock […] - 2025-05-19 05:14:54
The Manufacturers Life Insurance Company Increases Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
The Manufacturers Life Insurance Company increased its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 9.1% during the 4th quarter, Holdings Channel reports. The firm owned 9,373 shares of the biotechnology company’s stock after acquiring an additional 779 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Ligand Pharmaceuticals were worth […] - 2025-05-14 08:10:50
Ligand Pharmaceuticals (NASDAQ:LGND) Cut to “Sell” at StockNews.com
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Monday. Several other brokerages also recently commented on LGND. Oppenheimer raised their price objective on Ligand Pharmaceuticals from $142.00 to $145.00 and gave the stock an “outperform” […] - 2025-05-14 06:10:53
Price T Rowe Associates Inc. MD Raises Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Price T Rowe Associates Inc. MD grew its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 13.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,518 shares of the biotechnology company’s stock after buying an additional 1,781 […] - 2025-05-09 08:47:11
Ligand Pharmaceuticals Reiterates FY25 Outlook - Update
(RTTNews) - While reporting financial results for the first quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) reiterated its adjusted earnings and revenue guidance for fiscal 2025. - 2025-05-08 11:44:43
Hsbc Holdings PLC Grows Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Hsbc Holdings PLC raised its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 19.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,764 shares of the biotechnology company’s stock after buying an additional 605 shares during the quarter. Hsbc Holdings PLC’s […] - 2025-05-08 08:22:52
Mariner LLC Invests $276,000 in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Mariner LLC acquired a new stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) during the 4th quarter, HoldingsChannel reports. The institutional investor acquired 2,574 shares of the biotechnology company’s stock, valued at approximately $276,000. Other large investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC grew its […] - 2025-05-06 07:40:47
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Sold by Barclays PLC
Barclays PLC cut its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 8.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,972 shares of the biotechnology company’s stock after selling 3,484 shares during the period. […] - 2025-04-28 07:59:05
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Holdings Lifted by Sterling Capital Management LLC
Sterling Capital Management LLC lifted its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 825.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 546 shares of the biotechnology company’s stock after buying an additional 487 shares during […] - 2025-04-24 09:31:07
Legal & General Group Plc Acquires 214 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Legal & General Group Plc grew its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 0.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 57,838 shares of the biotechnology company’s stock after purchasing an additional 214 shares during the quarter. Legal & General Group Plc’s holdings in Ligand […] - 2025-04-21 08:08:55
Ligand Pharmaceuticals (NASDAQ:LGND) Upgraded to “Hold” at StockNews.com
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday. Other equities analysts have also recently issued reports about the company. Barclays increased their price target on Ligand Pharmaceuticals from $150.00 to $160.00 and gave […] - 2025-04-17 08:04:59
Geode Capital Management LLC Buys 10,171 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Geode Capital Management LLC increased its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 438,441 shares of the biotechnology company’s stock after acquiring an additional 10,171 shares during […] - 2025-04-15 08:00:52
Norges Bank Invests $4.96 Million in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Norges Bank purchased a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm purchased 46,290 shares of the biotechnology company’s stock, valued at approximately $4,960,000. Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Loomis […] - 2025-04-10 08:02:50
Ligand Pharmaceuticals (NASDAQ:LGND) Lowered to Sell Rating by StockNews.com
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Monday. A number of other equities research analysts have also commented on the company. Benchmark reiterated a “buy” rating and issued a $135.00 target price on […] - 2025-04-09 05:35:02
Short Interest in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Increases By 22.4%
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 955,100 shares, an increase of 22.4% from the February 28th total of 780,100 shares. Currently, 5.4% of the shares of the company are […] - 2025-04-04 05:15:16
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Position Raised by Teacher Retirement System of Texas
Teacher Retirement System of Texas boosted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 20.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,413 shares of the biotechnology company’s stock after acquiring an additional 907 shares during the period. […] - 2025-03-31 07:28:57
Ligand Pharmaceuticals (NASDAQ:LGND) Upgraded to “Hold” at StockNews.com
StockNews.com upgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning. Other equities research analysts have also issued research reports about the stock. Royal Bank of Canada raised their target price on shares of Ligand Pharmaceuticals from $141.00 […] - 2025-03-19 06:32:52
Ligand Pharmaceuticals (NASDAQ:LGND) Downgraded by StockNews.com to “Sell”
StockNews.com downgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a hold rating to a sell rating in a report published on Monday morning. Several other analysts also recently commented on LGND. Royal Bank of Canada raised their price objective on shares of Ligand Pharmaceuticals from $141.00 to $143.00 and gave the company an […] - 2025-03-11 05:55:01
Amalgamated Bank Has $592,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Amalgamated Bank grew its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,526 shares of the biotechnology company’s stock after acquiring an additional 177 shares during the period. Amalgamated […] - 2025-03-05 10:26:55
New York State Common Retirement Fund Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
New York State Common Retirement Fund lifted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 7.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 92,418 shares of the biotechnology company’s stock after buying an additional 6,123 shares during the […] - 2025-02-26 09:36:57
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Louisiana State Employees Retirement System
Louisiana State Employees Retirement System boosted its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,100 shares of the biotechnology company’s stock after buying an additional 300 shares […] - 2025-02-18 08:25:05

LGND institutional holdings

The following institutional investment holdings of LGND have been identified

Date ETF ISIN/Name Num Shares Book value
2025-06-26 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 11,991USD 1,387,239 0.0%
2025-06-26 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 1,570USD 181,633
2025-06-26 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 23,869USD 2,761,405
2025-06-26 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 9,634USD 1,114,557
2025-06-26 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 9,634USD 1,114,557
2025-06-26 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 101USD 11,685
Total =56,799 USD 6,571,076
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.